Senior Writer, National Biotech Columnist
Adam Feuerstein is a Senior Writer and National Biotech Columnist. He focuses on various aspects of medicine and healthcare, including immunology, oncology, and pharmaceutical regulation, while also covering health news and alternative medicine. Adam's insights and expertise have been featured in The Boston Globe, RamaOnHealthcare, STAT News, and TheStreet.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Adam Feuerstein's coverage primarily revolves around the healthcare and pharmaceutical industry, with a strong emphasis on providing data-driven insights and expert commentary. He frequently references press releases and cites data to support his reporting.
To effectively reach out to Adam, consider offering access to exclusive data or research findings related to biotech, healthcare, pharmaceuticals, drug development, or FDA approval processes. Additionally, experts who can provide insightful analysis of industry trends or specific events will likely capture his attention.
As Adam's geographic focus is not specified but he covers global pharmaceutical and biotech industries extensively; therefore relevant information from any part of the world would be valuable for him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Adam Feuerstein
Save stories to read later, available anytime from your account.
By: Adam Feuerstein
MADRID — The combination of an experimental drug from Tango Therapeutics and Revolution Medicines' Rasonque led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, clinical trial results reported Friday showed.
This week on the “The Readout LOUD” podcast, we remember our beloved colleague Helen Branswell, who died last week. We speak with colleagues, family, and public health leaders about her work and her legacy.
By: Adam Feuerstein, Andrew Joseph
Save stories to read later, available anytime from your account.
Save stories to read later, available anytime from your account.
Save stories to read later, available anytime from your account.
By: Adam Feuerstein
MADRID — A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer — results, the biotech said, that support its prior decision to advance the treatment into a late-stage clinical trial.
By: Adam Feuerstein
A Phase 3 trial of a targeted drug developed by Merck and China’s Kelun-Biotech cut by one-third the risk of death in patients with advanced endometrial cancer
By: Andrew Joseph, Adam Feuerstein
One of the more impressive data sets at this year's ESMO came from a Roche study of its drug divarasib, which inhibits G12C KRAS mutations, in second-line advanced non-small cell lung cancer, where it outpaced older KRAS inhibitors from Amgen and Bristol Myers Squibb.
By: Adam Feuerstein
This story is republished from STAT , the health and medicine news site that's a partner to the Globe. Sign up for STAT's free Morning Rounds newsletter here
